Tracking the staying power of a leukemia drug

NCT ID NCT05645172

Ongoing Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study aims to understand how long patients with chronic lymphocytic leukemia (CLL) continue taking the drug acalabrutinib in real-world German clinics. It will follow 137 patients for up to two years to see who stays on the treatment and why some might stop. The goal is to gather real-world data on treatment patterns, effectiveness, and quality of life to help improve future patient care.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

D Ren, Germany, 52353, Germany
Research Site

Herrsching am Ammersee, Germany, 82211, Germany
Research Site

L Rrach, Germany, 79539, Germany
Research Site

M Nchen, Germany, 80804, Germany
Research Site

M Nchen, Germany, 81377, Germany
Research Site

N Rnberg, Germany, 90449, Germany
Research Site

Neustadt Am R Benberge, Germany, 31535, Germany
Research Site

Saarbr Cken, Germany, 66113, Germany
Research Site

Sindelfinden, Germany, 71065, Germany
Research Site

W Rselen, Germany, 52146, Germany
Research Site

Amberg, 92224, Germany
Research Site

Aschaffenburg, 63739, Germany
Research Site

Augsburg, 86150, Germany
Research Site

Bad Homburg, 61352, Germany
Research Site

Bad Liebenwerda, 04924, Germany
Research Site

Bautzen, 02625, Germany
Research Site

Berlin, 10117, Germany
Research Site

Berlin, 13055, Germany
Research Site

Berlin, 13156, Germany
Research Site

Bonn, 53115, Germany
Research Site

Dachau, 85221, Germany
Research Site

Delitzsch, 04509, Germany
Research Site

Dessau, 06487, Germany
Research Site

Dortmund, 44263, Germany
Research Site

Erfurt, 99084, Germany
Research Site

Erfurt, 99085, Germany
Research Site

Essen, 45136, Germany
Research Site

Frankfurt am Main, 60596, Germany
Research Site

Frankfurt am Main, 65929, Germany
Research Site

Garbsen, 30823, Germany
Research Site

Halle, 06110, Germany
Research Site

Hanover, 30161, Germany
Research Site

Hanover, 30625, Germany
Research Site

Heide, 25746, Germany
Research Site

Herten, 45699, Germany
Research Site

Hof, 04509, Germany
Research Site

Kulmbach, 95326, Germany
Research Site

Laatzen, 30880, Germany
Research Site

Landshut, 72764, Germany
Research Site

Lebach, 66822, Germany
Research Site

Leipzig, 04103, Germany
Research Site

Leipzig, 04289, Germany
Research Site

Moers, 47441, Germany
Research Site

Naunhof, 04683, Germany
Research Site

Oldenburg, 26121, Germany
Research Site

Paderborn, 33098, Germany
Research Site

Pasing, 81281, Germany
Research Site

Pirna, 01796, Germany
Research Site

Porta Westfalica, 32457, Germany
Research Site

Potsdam, 14482, Germany
Research Site

Remscheid, 42859, Germany
Research Site

Reutlingen, 72764, Germany
Research Site

Riesa, 01589, Germany
Research Site

Saalfeld, 07318, Germany
Research Site

Schkeuditz, 04435, Germany
Research Site

Schorndorf, 73614, Germany
Research Site

Siegburg, 53721, Germany
Research Site

Straubing, 94315, Germany
Research Site

Twistringen, 27239, Germany
Research Site

Weiden, 92637, Germany
Research Site

Zittau, '02763, Germany

Conditions

Explore the condition pages connected to this study.

CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)